Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
Bożena Sosnowska, Janina Stępińska, Przemysław Mitkowski, et al.
Archives of Medical Science (2024) Vol. 20, Iss. 1, pp. 8-27
Open Access | Times Cited: 18

Showing 18 citing articles:

2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders.
Bogdan Solnica, Grażyna Sygitowicz, Dariusz Sitkiewicz, et al.
Archives of Medical Science (2024)
Open Access | Times Cited: 9
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)
Maciej Banach, Željko Reiner, Stanisław Surma, et al.
Drugs (2024)
Open Access | Times Cited: 7
Lipoprotein(a) and its impact on cardiovascular disease – the Polish perspective: Design, and first results of the Zabrze-Lipoprotein(a) Registry
Krzysztof Dyrbuś, Zofia Kułaczkowska, Karolina Konsek, et al.
Archives of Medical Science (2024) Vol. 20, Iss. 4, pp. 1069-1076
Open Access | Times Cited: 5
Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk
Tarek Harb, Efthymios Ziogos, Roger S. Blumenthal, et al.
European Heart Journal Open (2024) Vol. 4, Iss. 5
Open Access | Times Cited: 5
Association between Lp(a) and T2D: A Mendelian Randomization Study
Marcin Goławski, Mateusz Lejawa, Maciej Banach, et al.
Archives of Medical Science (2024) Vol. 20, Iss. 3, pp. 1002-1005
Open Access | Times Cited: 3
The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the polish population. The first results from the PMMHRI-Lp(a) registry
Bożena Sosnowska, Joanna Lewek, Weronika Adach, et al.
Progress in Cardiovascular Diseases (2024) Vol. 86, pp. 54-61
Open Access | Times Cited: 3
Lipoprotein (a) measurement: potential for personalized cardiovascular disease management in a patient with acute myocardial infarction
Jakub Michał Zimodro, Aleksandra Gąsecka, Piotr Arski, et al.
Archives of Medical Science (2024) Vol. 20, Iss. 3, pp. 1043-1047
Open Access | Times Cited: 2
It is Time to Address the Contribution of Cholesterol in all APOB-Containing Lipoproteins to Atherosclerotic Cardiovascular Disease
Peter P. Tóth, Maciej Banach
European Heart Journal Open (2024) Vol. 4, Iss. 4
Open Access | Times Cited: 2
Lipoprotein(a) and the atherosclerotic burden – should we wait for clinical trial evidence before taking action?
Isabella Fichtner, Chiara Macchi, Alessandra Stefania Rizzuto, et al.
Atherosclerosis Plus (2024) Vol. 58, pp. 16-23
Open Access | Times Cited: 2
Lipoprotein (a) and the Occurrence of Lipid Disorders and Other Cardiovascular Risk Factors in Patients without Diagnosed Cardiovascular Disease
Jakub Ratajczak, Aldona Kubica, Łukasz Pietrzykowski, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4649-4649
Open Access | Times Cited: 1
New data allow to better understand the secrets of lipoprotein(a): is that for sure?
Stanisław Surma, Bożena Sosnowska, Željko Reiner, et al.
European Heart Journal Open (2024) Vol. 4, Iss. 5
Open Access | Times Cited: 1
Clinical reality and challenges with familial hypercholesterolemia patients' management. 2024 results from the Regional Center for Rare Diseases (RCRD) Registry in Poland
Joanna Lewek, Bożena Sosnowska, Ewa Starostecka, et al.
International Journal of Cardiology (2024), pp. 132667-132667
Closed Access | Times Cited: 1
Guidelines of the Polish Society of Laboratory Diagnosticsand the Polish Lipid Association on laboratory diagnosticsof lipid metabolism disorders. 2024
Bogdan Solnica, Grażyna Sygitowicz, Dariusz Sitkiewicz, et al.
Diagnostyka Laboratoryjna (2024) Vol. 60, Iss. 1, pp. 1-24
Closed Access
Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation
Stanisław Surma, Michał Zembala, Bogusław Okopień, et al.
International Journal of Cardiology Cardiovascular Risk and Prevention (2024) Vol. 22, pp. 200297-200297
Open Access
Polymorphism rs662 (Q192R) of paraoxonase-1 and susceptibility to atherosclerosis of the coronary arteries
Małgorzata Barańska, Mariola Rychlik‐Sych, Michał Dudarewicz, et al.
Archives of Medical Science (2024) Vol. 20, Iss. 4, pp. 1328-1333
Open Access
Lp(a) and thromboembolism: current state of knowledge and unsolved issues
Małgorzata Konieczyńska, Joanna Natorska, Michał Ząbczyk, et al.
Archives of Medical Science (2024)
Open Access
Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs
Aleksandra Krzesińska, Joanna Marlęga-Linert, Gabriela Chyła-Danił, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13597-13597
Open Access
Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice
A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, et al.
Russian Journal of Cardiology (2024) Vol. 29, Iss. 12, pp. 6177-6177
Open Access
Page 1

Scroll to top